Journals / Literatür Eczacılık Bilimleri Dergisi / 2020 / Cilt: 9 - Sayı: 2

The Role of MMP-2 and MMP-9 in Breast Cancer

Meme Kanserinde MMP-2 ve MMP-9’un Rolü

Pages
116–124
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this re- view, in breast cancer MMP-2 and MMP-9 role, polymorphisms, in- teractions that increase the expression / activity of these enzymes, and their inhibition with molecules will be presented and studies con- ducted in recent years will be presented.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Matrix metalloproteinases (MMPs) are a family of cal- cium and zinc-dependent proteolytic enzymes.
📊
Key Findings & Data:MMP-2 and MMP-9 are members of this family; type IV collagenases which degrade gelatin, types IV, V, VII and X collagen.
💡
Conclusion & Impact:In this re- view, in breast cancer MMP-2 and MMP-9 role, polymorphisms, in- teractions that increase the expression / activity of these enzymes, and their inhibition with molecules will be presented and studies con- ducted in recent years will be presented.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Matrix metalloproteinases (MMPs) are a family of cal- cium and zinc-dependent proteolytic enzymes. MMP-2 and MMP-9 are members of this family; type IV collagenases which degrade gelatin, types IV, V, VII and X collagen. MMP-2 is synthesized by fi- broblasts, endothelial cells and osteoblasts, MMP-9 is synthesized by inflammatory cells, tumor cells, keratinocytes and epithelial cells. Gelatinases are secreted as inactive zymogens and turn into active forms by dividing prodomains. MMP-2 and MMP-9 cause prolifera- tion, migration, invasion and metastasis in breast cancer cells. There are studies investigating the polymorphisms and expressions/activities of both MMP-2 and MMP-9 for breast cancer treatment. Due to their important role in breast cancer progression and metastasis, common functional polymorphisms of these enzymes have been reported to contribute to breast cancer development with their phenotypic prop- erties, including patient survival. Di-2-Ethylhexylphthalate, PAX6, cellular prion protein, Natriuretic peptide receptor A, active leuko- cyte cell adhesion molecule, EZH2, interaction of eGFR with ligand EGF, interaction with integrin and non-integrin receptors, with TF- FVIIa / trypsin mediated protease of receptor 2 activation is shown to increase expression of MMP-2 and / or MMP-9. There are studies on Alisol A, Casticin, Orientin, Luteolin and [15] pyN5 and [16] pyN5 to inhibit MMP-2 and MMP-9 as potential treatment targets due to their effects on invasion and metastasis in breast cancer. In this re- view, in breast cancer MMP-2 and MMP-9 role, polymorphisms, in- teractions that increase the expression / activity of these enzymes, and their inhibition with molecules will be presented and studies con- ducted in recent years will be presented.

Özet

Matriks metalloproteinaz (MMP)lar kalsiyum ve çinko bağımlı proteolitik enzim ailesidir. Bu ailenin bir üyesi olan MMP-2 ve MMP- 9 jelatini, tip IV, V, VII ve X kollajeni parçalayan tip IV kollajenaz- lardır. MMP-2 fibroblastlar, endotel hücreleri ve osteoblastlar; MMP-9 inflamatuar hücreler, tümör hücreleri, keratinositler ve epitel hücreleri tarafından sentezlenmektedir. Jelatinazlar, zimojen olarak salgılanırlar ve prodomainlerin bölünmesi ile aktif formlarına dönüşürler. MMP-2 ve MMP-9, meme kanseri hücrelerinde proliferasyon, migrasyon, in- vazyon ve metastaza yol açmaktadır. Hem MMP-2’nin hem de MMP- 9’un, meme kanseri tedavisine yönelik olarak polimorfizmlerini ve ekspresyonlarını/aktivitelerini araştıran çalışmalar bulunmaktadır. Meme kanseri progresyonu ve metastazındaki önemli rolleri nedeni ile bu enzimlerin ortak fonksiyonel polimorfizmlerinin, hasta sağkalımını da içeren fenotipik özellikleriyle meme kanseri gelişimine katkıda bu- lunduğu bildirilmektedir. Di-2-Etilheksilfitalat, PAX6, hücresel prion proteini, natriüretik peptid reseptörü A, aktif lökosit hücre adezyon mo- lekülü, EZH2, eGFR’nin ligand EGF ile etkileşimi, integrin ve integ- rin olmayan reseptörlerle etkileşim, TF-FVIIa/tripsin aracılı proteaz ile reseptör 2’nin aktivasyonu ile MMP-2 ve/veya MMP-9’un ekspresyo- nunun arttığı gösterilmektedir. Meme kanserinde invazyon ve metastaz üzerindeki etkileri nedeni ile potansiyel tedavi hedefi olarak MMP-2 ve MMP-9’u inhibe etmeye yönelik olarak Alisol A, Casticin, Orientin, Luteolin ve [15]pyN5 ve [16]pyN5 üzerinde yapılan çalışmalar bulun- maktadır. Bu derlemede, meme kanserinde MMP-2 ve MMP-9’un rolü, polimorfizmleri, bu enzimlerin ekspresyonunu/aktivitesini artıran etki- leşimleri, moleküller ile inhibisyonları incelenecek ve son yıllarda ya- pılan çalışmalar sunulacaktır.

🔖

Cite This Article

TAŞKAN, T., GÖNENÇ, A. (2020). The Role of MMP-2 and MMP-9 in Breast Cancer. Literatür Eczacılık Bilimleri Dergisi, Cilt: 9 - Sayı: 2, 116–124. https://ajindex.com/articles/274401

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Scherer S, De Souza TB, De Paoli J, Brenol CV, Xavier RM, Brenol JC, et al. Matrix met- alloproteinase gene polymorp-hisms in pa- tients with rheumatoid arthritis. Rheumatol Int. 2010
  2. 30(3):369-73 [Crossref] [PubMed] 2. Djurić T, Stojković L, Zivković M, Končar I, Stanković A, Djordjević A, Alavantić D. Matrix metalloproteinase-1 promoter genotypes and haplotypes are associated with carotid plaque presence. Clin Biochem. 2012
  3. 45(16-17): 1353-6.[Crossref] [PubMed] 3. Zivković M, Djurić T, Dincić E, Raicević R, Alavantić D, Stanković A. Matrix metallopro- teinase-9 −1562 C/T gene polymorphism in Serbian patients with multiple sclerosis. J Neu- roimmunol. 2007
  4. 189(1-2):147-50. [Crossref] [PubMed] 4. Bode W, Fernandez-Catalan C, Tschesche H, Grams F, Nagase H, Maskos K. Structural properties of matrix metalloproteinases. Cell Mol Life Sci. 1999
  5. 55(4):639-52.[Crossref] [PubMed] 5. Nagase H, Woessner Jr JF. Matrix metallo- proteinases. J Biol Chem. 1999
  6. 274(31): 21491-4. [Crossref] [PubMed] 6. Sternlicht MD, Werb Z. How matrix metallo- proteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001
  7. [Crossref] [PubMed] [PMC] 7. Murphy G, Nagase H. Progress in matrix met- alloproteinase research. Mol Aspects Med. 2008
  8. 29(5):290-308. [Crossref] [PubMed] [PMC] 8. Gill SE, Kassim SY, Birkland TP, Parks WC. Mouse models of MMP and TIMP function. Methods Mol Biol. 2010
  9. [Crossref] [PubMed] 9. Itoh Y, Ito N, Nagase H, Evans RD, Bird SA, Seiki M. Cell surface collagenolysis requires homodimerization of the membrane-bound collagenase MT1-MMP. Mol Biol Cell. 2006
  10. 17(12):5390-9. [Crossref] [PubMed] [PMC] 10. Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature. 1995
  11. 375(6528):244-7. [Crossref] [PubMed] 11. Pei D, Weiss SJ. Transmembrane-deletion mutants of the membrane-type matrix metal- loproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem. 1996
  12. 271(15):9135-40. [Crossref] [PubMed] 12. Cathcart J, Pulkoski-Gross A, Cao J. Target- ing matrix metalloproteinases in cancer: bring- ing new life to old ideas. Genes Dis. 2015
  13. 2(1):26-34. [Crossref] [PubMed] [PMC] 13. Bauvois B. New facets of matrix metallopro- teinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relation- ship to tumor progression. Biochim Biophys Acta. 2012
  14. 1825(1):29-36.[Crossref] [PubMed] 14. Agnieszka Jezierska, Tomasz Motyl. Matrix Metalloproteinase-2 involvement in